Coronavirus researchers looking for smart-ring wearers

The Finnish maker of the Oura health-tracking finger ring is sponsoring a two-pronged, AI-aided COVID-19 study at the University of California, San Francisco (UCSF).

One arm of the research will look for signs of the virus in 2,000 ring-equipped healthcare workers who have daily contact with UCSF Health patients. The other will be open to anyone who already uses the ring.

Drawing data from ring-wearers’ body temperature, respiration and heart rate, the team will concurrently ask participants to complete daily surveys on symptoms of illness.

From these information feeds the researchers will build an algorithm to spot patterns of onset, progression and recovery. Their hope is that the AI-guided approach will inform best COVID-19 care practices going forward.

In addition, the project, called TemPredict, could “open the door for research into tracking and managing other illnesses and conditions,” according to an announcement from Oura, whose U.S. headquarters are in San Francisco.

Click here for the announcement and here if you’re an Oura user interested in participating.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup